CORPORATE
CORPORATE
PROFILE
| Company Name | Metcela Inc. |
|---|---|
| Founded | March 9, 2016 |
| Outline of Business | Research and development of stem cell and fibroblast-based therapies for cardiac diseases |
ACCESS
Life Innovation Center
3-25-22 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0821
HISTORY
- 2014
- Launched Project Metcela
- 2016.03
- Metcela Inc., co-founded by Takahiro Iwamiya and Kenichi Nogami (Keio University spin-off)
- 2016.06
- Chosen for STS grant (JPY 70M) from NEDO
- 2017.03
- Chosen for SCA grant (JPY 70M) from NEDO
- 2017.04
- Initiated joint research with University of Tsukuba
- 2018.07
- Chosen for Hashiwatashi grant from NEDO
- 2018.09
- Raised $4.6 Million in Series A Financing Round
- 2018.12
- Headquartered in Kawasaki City, Kanagawa Prefecture
- 2019.06
- Selected for J-Startup 2019, a government-led initiative for supporting startups
- 2020.06
- Signed a business partnership agreement with Japan Lifeline Co., Ltd.
- 2021.01
- Secured $12.7 Million in Series B Financing Round
- 2021.07
- Initiated Phase 1 clinical trial for chronic ischemic heart failure
- 2022.04
- Acquired Japan Regenerative Medicine Co., Ltd.
- 2022.06
- Mergered with Japan Regenerative Medicine Co., Ltd.
- 2022.06
- Raised $14 Million in Series C Financing Round
- 2022.11
- Chosen for CiCLE grant program from AMED